• 1. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Research Briefing on 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol (CAS: 40534-33-6) in Chemical Biology and Pharmaceutical Applications

1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol (CAS: 40534-33-6) is a pyrazole derivative that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting kinase inhibition and inflammation pathways. Recent studies have highlighted its role in the development of novel therapeutics for cancer, autoimmune diseases, and neurological disorders.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol as a building block for selective JAK2 inhibitors. The researchers utilized this compound to develop a series of derivatives showing nanomolar potency against JAK2 while maintaining excellent selectivity over other JAK isoforms. This specificity is crucial for reducing off-target effects in myeloproliferative disorder treatments.

In the field of oncology, a recent patent application (WO2023051234) disclosed novel EGFR inhibitors incorporating the 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol scaffold. The disclosed compounds showed remarkable activity against EGFR L858R/T790M mutations, which are associated with resistance to first-generation EGFR inhibitors in non-small cell lung cancer. Molecular modeling studies revealed that the hydroxyl group in this compound plays a critical role in forming hydrogen bonds with the kinase domain.

From a synthetic chemistry perspective, advances in the production of 40534-33-6 have been reported in Organic Process Research & Development (2024). The new catalytic asymmetric reduction protocol achieves >99% ee with 90% yield, addressing previous challenges in stereoselective synthesis. This improvement is particularly important as the stereochemistry of this compound significantly impacts its biological activity when incorporated into drug candidates.

The compound's potential in CNS drug development was highlighted in a recent ACS Chemical Neuroscience publication (2024), where it served as a precursor for novel mGluR5 negative allosteric modulators. These modulators showed improved blood-brain barrier penetration compared to previous generations, with the 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol moiety contributing to optimal lipophilicity (clogP 2.1) and polar surface area (75 ?2).

Ongoing clinical trials (NCT05678954) are evaluating a TLR7/8 dual antagonist containing this structural motif for autoimmune disease treatment. Preliminary results presented at the 2024 American Chemical Society meeting showed significant reduction in pro-inflammatory cytokines (IL-6, TNF-α) with favorable safety profiles, suggesting this chemical scaffold may offer advantages over existing immunomodulators.

In conclusion, 1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol continues to emerge as a privileged structure in medicinal chemistry. Its versatility, demonstrated across multiple therapeutic areas and target classes, combined with recent synthetic improvements, positions this compound as a valuable asset in drug discovery pipelines. Future research directions may explore its application in PROTAC design and covalent inhibitor development, leveraging its optimal physicochemical properties and synthetic accessibility.

• 799260-82-5(1,2,3,4-Butanetetrol,1-(1-methyl-1H-pyrazol-4-yl)-, (1R,2S,3R)-)
• 799260-83-6(1,2,3,4-Butanetetrol,1-(1-methyl-1H-pyrazol-4-yl)-, (1R,2R,3R)-)
• 112029-98-8((1-Methyl-1H-pyrazol-4-yl)methanol)
• 1340063-91-3(1-Methyl-4-(oxiran-2-yl)-1H-pyrazole)
• 1007462-84-1(1-(1-ethyl-1H-pyrazol-4-yl)ethan-1-ol)
• 1306728-57-3((1R)-1-(1-Methyl-1H-pyrazol-4-yl)ethan-1-ol)
• 1247411-50-2(2-(1-methyl-1H-pyrazol-4-yl)propan-2-ol)
• 1248787-82-7(1-(1-methyl-1H-pyrazol-4-yl)cyclopropan-1-ol)
• 1152927-77-9(2-amino-1-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol)
• 176661-75-9(2-(1-methyl-1H-pyrazol-4-yl)ethan-1-ol)